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Abstract
Purpose—This study evaluated the feasibility and preliminary efficacy of two 6-month, self-
regulation interventions that focused on daily self-weighing (DSW), and used objective monitoring 
and tailored feedback about weight (±activity), to prevent weight gain among African American 
breast cancer survivors.
Methods—Participants (n=35) were randomized to an intervention + activity monitoring (INT+), 
intervention (INT), or control (CON) group. Interventions included a wireless scale (±activity 
tracker) that transmitted objective data to a mobile app/website, emailed lessons, and tailored 
feedback based on objective weight (±activity data). Participants completed in-person and online 
assessments at baseline, 3 and 6 months.
Results—Ninety-four percent of participants completed assessments at 3 months, and 97% at 6 
months. Median (IQR) weight change after 6 months was −0.9% (−4.4−0.1) in the INT+ 
(p=0.075; p=0.067 vs. CON) and −0.2% (−4.2−1.3) in the INT groups (p=0.463; p=0.357 vs. 
CON), versus a 0.2% (−0.7−1.7) gain in the CON group. The proportion of INT+, INT and CON 
participants that were at or below baseline weight was 72.7%, 53.8% and 45.5% respectively 
(effect sizes d=.64, d=.18). Most INT+ participants weighed and wore trackers ≥5 days/week (INT
+, 81.9% vs. INT, 38.5% vs. CON, 0%; p< 0.0005; INT+, 72.7%). Both intervention groups 
perceived DSW as positive, and 100% would recommend the program to other breast cancer 
survivors.
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Conclusion—An intervention focused on DSW as a self-monitoring strategy shows promise for 
preventing weight gain in breast cancer survivors.
Implications for Cancer Survivors—Daily self-monitoring of weight and activity may be a 
feasible and accessible approach to promote weight gain prevention in breast cancer survivors.
Keywords
breast cancer survivors; African American; randomized trial; weight gain prevention; intervention; 
technology
INTRODUCTION
Breast cancer is the most commonly diagnosed cancer among women worldwide [1]. There 
are an estimated 3.1 million female breast cancer survivors in the United States [2]. Women 
often experience weight gain after breast cancer diagnosis, which increases risks for 
comorbidities, fatigue, functional decline and poorer quality of life [3–4]. Observational 
studies have demonstrated that breast cancer survivors who gain 5–10% or more above 
prediagnosis weight have poorer survival [5,6], and weight gain over time is associated with 
increased cardiovascular disease and diabetes risk factors [7,8], which are already prevalent 
comorbidities among cancer survivors [3,9]. In contrast, weight maintenance in the first 2–3 
years after breast cancer diagnosis is associated with improved survival [5,6]. Thus, 
preventing weight gain in breast cancer survivors is an important public health goal that can 
have considerable impact by decreasing risk for comorbidities and enhancing survival 
outcomes [3,5,6].
African American breast cancer survivors are more likely to experience obesity and cancer-
related comorbidities relative to other women [10,11] and may be at higher risk for weight 
gain after diagnosis [12]. Only a handful of weight control interventions have focused 
specifically on African American breast cancer survivors [13]. Although these small studies 
have shown promise, they have targeted weight loss after treatment [14–16], dietary change 
[17] or weight loss maintenance [18], and only two were randomized trials. The few studies 
that have tested lifestyle interventions to prevent weight gain among women with breast 
cancer were during treatment and among predominantly White populations [19–23]. Self-
regulation of weight through frequent self-weighing is a feasible and potentially scalable 
approach to supporting weight maintenance among adult populations [24–28]. Previous 
interventions based on a self-regulation approach that have encouraged daily self-weighing 
and taught individuals to make small changes in diet and exercise behaviors based on daily 
weight information have been effective in preventing weight gain in young adults [29–31]. 
Distance- and technology-based lifestyle interventions have the potential to enhance access 
to cost-effective weight control programs for the growing population of cancer survivors 
[32]. Although non face-to-face interventions have been effective for weight loss [33–36] 
and maintenance among cancer survivors [37], few have used web-based or mobile 
technologies [32,38,39] or focused on minority populations of cancer survivors [32,38].
Among overweight and obese racial/ethnic minority adults, electronic health interventions 
have demonstrated short-term and modest weight loss outcomes, while the efficacy of 
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mobile health interventions is largely unknown [40]. The emergence of smart scales and 
wearable activity trackers represents a unique opportunity to use distance-based objective 
self-monitoring tools to encourage daily self-monitoring in the context of weight 
management interventions. In a pilot randomized trial of a 12-week smartphone-based 
weight loss intervention for overweight and obese adults (n=40; 27.5% minorities) that used 
a wireless scale and activity tracker for self-monitoring, the intervention group achieved 
clinically significant weight loss compared to a health education group [41]. Among breast 
cancer survivors (n=29; 3% minorities), Spark et al. [39] evaluated a 6-month tailored text-
messaging intervention to promote weight maintenance after completion of a 6-month 
telephone-delivered weight loss intervention and found that participants had lost 5.2% on 
average of baseline weight after 18 months. While these technology-based weight control 
interventions show initial promise, few racial/ethnic minority participants were included, 
and little is known about the acceptability of digital scales and activity trackers for 
facilitating weight gain prevention among African American women or breast cancer 
survivors. To date, no randomized weight gain prevention trials have been conducted in post-
treatment breast cancer survivors; few behavioral interventions for breast cancer survivors 
have focused on minority populations [13,42] or used digital scales and activity trackers for 
objective self-monitoring.
The WELL (Weighing Every day for Love of Life and) Body study aimed to capitalize on 
the potential of wireless scales and activity trackers to deliver real-time guidance and 
individualized feedback tailored in response to objectively monitored weight and activity 
patterns. Therefore, the purpose of this pilot study was to evaluate the feasibility and 
preliminary efficacy of two 6-month, remotely-delivered, self-regulation interventions that 
focused on daily self-weighing and used objective monitoring and tailored feedback on 
weight only, or weight plus activity, to promote weight gain prevention among African 
American breast cancer survivors. We hypothesized that a self-regulation approach would be 
feasible and that participants randomly assigned to the self-regulation plus activity 
monitoring or self-regulation intervention groups would have a lower magnitude of weight 
gain at 6 months compared to those in the control group.
METHODS
Study Design
This 3-arm pilot randomized trial evaluated the feasibility of two self-regulation 
interventions (intervention plus activity monitoring or intervention, hereafter referred to as 
INT+ and INT) compared to a control group among African American breast cancer 
survivors. Both 6-month interventions were aimed at preventing weight gain through the 
self-regulation of eating and exercise behaviors. Given that weight loss interventions have 
had limited success in achieving clinically meaningful weight loss among African American 
breast cancer survivors [14–18], focusing on weight gain prevention could be a feasible 
alternative approach to promoting weight management in this population, as messages 
regarding weight maintenance may be more culturally relevant [43], and weight gain can be 
prevented using technology-based intervention approaches delivered at a lower intensity 
than needed for weight loss [24, 43]. Participants were randomly assigned to one of 3 
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groups: self-regulation intervention with objective activity monitoring (INT+), self-
regulation intervention (INT), or delayed intervention control (CON). Follow-up 
assessments occurred at 3 and 6 months in a similar manner to baseline assessments, using 
online questionnaires and clinic measurements. Participants received $40 for completing 
each of the baseline, 3-month and 6-month online questionnaires and clinic assessments. All 
study procedures were reviewed and approved by the Protocol Review Committee of the 
UNC Lineberger Comprehensive Cancer Center and Institutional Review Board of the 
University of North Carolina at Chapel Hill.
Participants and Recruitment
Individuals were eligible to participate if they met the following inclusion criteria: female, 
age 18 or older; self-identify as African American or black; diagnosed with stage I–IIIA 
breast cancer within the last 10 years; body mass index (BMI) of 20–45 kg/m2; completed 
cancer treatment (except endocrine treatment); no evidence of progressive disease or second 
primary cancers; able to read, write and speak English; have access to the Internet and a 
computer on at least a weekly basis; use an Internet e-mail address or willing to sign up for a 
free email account; willing to be randomized; physician approval to participate.
Participants were recruited over a 9 month period in 2014 using multiple approaches to 
identify and contact potentially eligible women, including: calling individuals in a hospital-
based health registry/cancer survivorship cohort who had consented to be re-contacted about 
studies of potential interest, clinic-based in-person recruitment, and direct mailings to 
individuals identified through the local tumor registry. We also used community-based 
approaches, such as advertising at local community events with information tables and flyers 
and asking organizations to share recruitment information via social media and email. 
Recruitment advertisements directed interested individuals to a recruitment website with 
detailed study information and a link to a preliminary online screening questionnaire. Initial 
screening included questions about age, race/ethnicity, height, weight, and cancer diagnosis. 
Study staff contacted individuals who were initially eligible and completed screening by 
phone. Eligible and interested individuals were scheduled for a baseline assessment visit and 
received an email with a unique link to a secure online informed consent form and physician 
consent form for the participant to obtain medical clearance. Informed consent was obtained 
from all study participants via the online consent and in-person. After completion of 
baseline online questionnaires and clinic assessments, participants were randomly assigned 
to one of three groups in blocks of 6 with stratification by BMI 20–24.9 (normal weight) and 
BMI ≥25 (overweight or obese), since weight gain trajectories and ability to engage in 
regular activity may differ between these groups. The randomization sequence was 
generated by a research team member not involved in intervention delivery, who used a 
computer-based random number generator to produce the random allocation sequence and 
placed assignments in sealed, opaque envelopes. Data collection occurred between January 
2014 and June 2015 in Chapel Hill, NC.
Procedures for both Intervention Groups
Table 1 outlines the intervention approach and study components, which are described 
below. The goal of the interventions was to prevent weight gain through self-regulation of 
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behaviors, with an emphasis on daily self-weighing as the primary self-observation activity 
to monitor changes in weight and promote changes in eating and exercise behaviors, and in 
turn prevent weight gain. Participants in both intervention groups received: 1) a face-to-face 
individual session, 2) a Bluetooth and Wifi-enabled wireless scale (Withings WS-30, 
Cambridge, MA) [44] with access to a companion mobile app and website with graphs of 
weight trends; 3) 24 weekly email-delivered behavioral lessons; and 4) 24 weekly emails 
with tailored feedback on self-weighing and weight data. The intervention was based on 
self-regulation theory [45] and a framework successfully used in STOP Regain, which 
emphasized daily self-weighing and self-regulation of eating and exercise behaviors to 
prevent weight regain [25] and a more recent study of weight gain prevention for young 
adults, SNAP (Study of Novel Approaches to Prevention) which emphasized daily self-
weighing and either small changes on a daily basis or larger periodic changes [24,46].
After baseline assessment and randomization, an interventionist with PhD training in 
nutrition intervention conducted an initial one-hour face-to-face session. Participants 
received education about weight gain in breast cancer survivors, behaviors associated with 
body weight, and health consequences of weight gain. The session provided an overview of 
energy balance through diet and physical activity behaviors, the importance of self-weighing 
as an indicator of energy balance, and emphasized daily use of the wireless scale as a tool or 
indicator of progress with diet and physical activity behaviors. Participants received a 
wireless scale that was configured during the initial visit to automatically sync weight data 
with the individual’s online account and/or mobile app. Prior to randomization, the 
interventionist initialized a scale and set up a companion website profile for each participant. 
Participants in both intervention groups were instructed to monitor their weight by weighing 
themselves daily using the wireless scale and taught how to use the scale and access the 
Withings website (www.withings.com) or app for viewing weight trends over time. Research 
assistants retrieved objective weight-related data for each participant on a weekly basis to 
drive content for tailored feedback messages and collect process data on adherence.
Over 24 weeks, intervention participants received weekly email lessons from the 
interventionist that focused on skills and cognitive behavioral strategies that are commonly 
taught in standard behavioral weight control programs (e.g., self-monitoring, problem 
solving, finding social support). The instructional lessons were adapted from previous online 
weight control interventions (STOP Regain, SNAP) [24,25,46] to focus on breast cancer 
survivors and use daily self-weighing as the primary self-monitoring strategy to guide self-
regulation of eating and exercise behaviors. Lesson were 4–5 pages (standard letter size, 
accessed as PDF) with standardized content for all participants and a new topic each week. 
Intervention participants were taught to practice core self-regulation strategies, including: 1) 
weighing themselves daily; 2) comparing their current weight with their weight at study 
baseline to detect small weight changes as they occur; 3) implementing problem solving and 
behavioral strategies to deal with changes; 4) evaluating the success of these strategies; 5) 
providing self-reinforcement for successfully maintaining their weight, or making diet and 
physical activity changes if they were above their baseline weight. To help participants 
interpret daily weight data and take recommended actions based on their current weight, 
participants were taught to use a color zone monitoring approach adapted from the STOP 
Regain and SNAP interventions and outlined in Table 1 [24,25,46].
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During the intervention, participants were encouraged to make two changes each day, one 
change in their eating behavior and one change in their activity behavior, to prevent weight 
gain. Women were instructed to identify one small change in diet that would reduce their 
intake by approximately 100 kcal per day (e.g., drink 1 less soda per day) and received a 
recommendation and exercise plan to gradually increase their aerobic activity each week 
during the intervention until they reached 150–225 minutes per week of moderate-intensity 
physical activity (i.e., 3–5 metabolic equivalents (METs), 30–45 minutes on 5 days/week, 
consistent with current guideline for cancer survivors) [47].
Based on self-weighing frequency and weight change obtained from wireless scale data, 
participants received weekly tailored feedback messages recommending self-regulation 
skills and behavioral strategies. Feedback messages were tailored using an algorithm for 
self-weighing frequency (weighing 6–7 days vs. <6 days) and color zone for the week 
(green, yellow or red; see Table 1). Participants were instructed to practice either reinforcing 
themselves or taking recommended actions to bring their weight back to their weight at the 
beginning of the program. For instance, feedback encouraged participants to keep weighing 
daily or provided tips to support adoption of daily self-weighing. Additionally, messages 
provided reinforcement for current behaviors consistent with weight regulation (green zone) 
or offered new tips for reducing intake or increasing activity, and other evidence-based 
strategies for successful weight loss (yellow or red zone).
Additional Procedures for Self-regulation Intervention with Activity Monitoring
The INT+ group received all of the above and were asked to wear an activity tracker 
(Withings Pulse, Cambridge, MA) [48], which interfaced with the wireless scale and synced 
data to a single online account. The only difference between INT+ and INT group lessons 
was in the weekly homework; INT+ participants were encouraged to track their activity 
daily in addition to weighing themselves daily. Tailored feedback to participants in this 
group incorporated both objective physical activity monitoring information garnered from 
the activity tracker and weight data from the wireless scale. In addition to feedback on 
weight and daily self-weighing, the message provided specific feedback on whether 
participants were monitoring their activity and meeting their weekly exercise 
recommendation. The messages reinforced the importance of monitoring activity, of regular 
exercise for weight management, or provided specific strategies for adopting and 
maintaining physical activity behaviors.
Procedures for Control Group
The control group participants received a wireless scale at baseline for evaluation purposes, 
which allowed us to isolate the effects of our intervention from any potential effects related 
to the novelty of the scale and companion website/mobile app. In the initial face-to-face 
individual session, participants were blinded to the intervention focus on daily weighing 
during the 6-month study period (so as not to alter the natural frequency of self-weighing 
and history of weight gain) and were advised to maintain their current weighing behaviors. 
After 6 months, control participants received all of the INT group lessons with modified 
delivery of the intervention for 3 months. Given that they had already participated for 6 
months and to minimize the amount of time individuals had to wait to receive educational 
Valle et al. Page 6
J Cancer Surviv. Author manuscript; available in PMC 2018 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
materials, lessons were emailed to participants twice a week over 3 months and without 
weekly feedback emails.
Measures
Participants were assessed for all of the following measures at baseline, 3 and 6 months 
unless otherwise noted. Anthropometric and clinical data were collected by the 
interventionist or one other research staff member, using a standard protocol. Self-
monitoring data were downloaded weekly by a research assistant and reviewed by the 
interventionist for accuracy. All data were double-entered into a database by two of five 
trained doctoral students to ensure accuracy of data entry.
Demographics and other health-related variables—At baseline, participants were 
asked to report their age, education level, marital status, employment status, income, 
medication use, smoking behaviors, weight history, comorbid conditions and cancer history. 
At 3 and 6 month assessments, participants reported medication use and any health events.
Anthropometric and clinical measures—Weight was measured in light clothing, 
without shoes, on a calibrated digital scale (Tanita BWB 800) at each assessment visit. Two 
measures were completed and averaged. Height was determined to the nearest 0.1 cm at the 
baseline assessment visit using a wall-mounted stadiometer. The average of two height 
measures was used. Weight and height measures were used to calculate BMI (weight in 
kilograms divided by height in meters squared). Waist circumference was measured at 
exhale using a Gulick II tape measure at the midpoint between the highest point of the iliac 
crest and lowest part of the costal margin. Two measures of waist circumference were taken 
to the nearest 0.1 cm; if the difference exceeded 1.0 cm, a third measure was taken. Body 
composition was measured with the BodPod (COSMED, Concord, CA) after a 2-hour fast 
and refraining from strenuous exercise for 8 hours. Blood pressure was measured using a 
Dinamap Monitor Pro 100, while seated after a 5-minute rest period with cuff size 
determined by arm circumference. Three consecutive measurements, with a 30-second wait 
between each reading, were averaged. Hemoglobin A1c and blood lipids (triglycerides, total 
cholesterol, HDL and LDL) were assessed by fingerstick and analyzed using the Alere 
Afinion analyzer and the Alere Cholestech LDX analyzer respectively.
Adherence to self-monitoring—Self-weighing habits were objectively measured via the 
wireless scales, which sent weight data directly to a companion app and website 
(www.withings.com) accessible through an online profile. Weight data were downloaded 
weekly from participants’ online profiles and tabulated to derive total days weighed (out of a 
possible 168 program days), average days weighed per week (number of days weighed/24 
program weeks), and a measure of average weighing frequency of 5 or more days per week. 
A few participants (n=2) reported experiencing technical problems syncing weight data via 
the companion app or Wifi network. However, these were resolved with the assistance of the 
interventionist (e.g., update app, changed Wifi password), and self-weighing data from these 
participants were ultimately synced and collected.
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Objective self-monitoring of physical activity was assessed via the activity tracker, which 
transmitted activity data to the same companion app and website profile as the weight data. 
Daily activity data, including days tracked, were downloaded and recorded weekly for the 
INT+ group for the purpose of informing weekly tailored feedback. We calculated total days 
tracked, average number of days tracked per week and a measure of tracking on 5 or more 
days per week. Technical difficulties that arose with the trackers included getting them wet 
from sweat (n=1) or laundry (n=1), and a few participants lost them (n=3). Lost trackers 
were replaced and other issues were quickly resolved through troubleshooting with the 
interventionist, so that activity data were transmitted to participants’ website profiles.
Adherence to weight management strategies—At 6 months, intervention 
participants reported how often (1 = not at all to 8 = always) they used various strategies to 
control their weight over the past 6 months, including making 100-calorie diet changes to 
reduce intake, tracking dietary intake with an app or website, increasing daily steps, 
exercising at least 5 days a week, and wearing a pedometer or other activity monitor [24,46].
Diet—Dietary intake was measured at each assessment time point using the Automated 
Self-Administered 24-Hour Dietary Recall (ASA-24) developed by the National Cancer 
Institute [49], an online system that guides participants through a multi-pass recall of foods 
eaten over the previous 24 hours. Women were asked to complete a 24-hour recall twice 
(one weekday and one weekend day) at each time point to provide an accurate representation 
of typical consumption.
Physical activity—The Paffenbarger Activity Questionnaire (PAQ) was administered to 
all participants by an interviewer at each assessment visit to assess physical activity at each 
assessment period [50]. The PAQ has been used to assess leisure time activity in many 
weight loss trials and was scored to provide an estimate of calories expended per week in 
overall leisure time activity (using metabolic equivalents from the Compendium of Physical 
Activities [51].
Self-weighing habits and perceptions—Participants were asked how frequently they 
had weighed themselves within the past 3 months on a 7-point scale, ranging from several 
times a day to never [46,52]. Perceptions about daily self-weighing were assessed for the 
intervention groups at 6 months using items included in previous weight gain prevention and 
self-regulation interventions [30,46]. Items comprised questions about whether they found 
daily self-weighing to be positive, easy to remember, easy to do, helpful and were likely to 
continue weighing after study completion. Questions also asked whether participants 
perceived daily self-weighing to be frustrating, made them self-conscious, and provoked 
anxiety. Responses were on an 8-point scale, with higher scores indicating more favorable 
perceptions.
Program acceptability and satisfaction—At 6 months, intervention participants were 
asked how much of the email lessons and feedback emails they read (1= none to 4 = all/
most). Intervention participants also rated the eating and activity approaches (i.e., reducing 
intake by 100 calories per day, increasing activity each day) taught during the program using 
an 8-point scale, including the helpfulness, difficulty, confidence in the effectiveness of the 
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approaches for preventing weight gain, and confidence in continuing the approaches [53]. 
Higher scores indicated greater acceptability. Additional questions asked intervention group 
participants about the helpfulness of various program features for reaching their weight 
goals (e.g., smart scale, activity tracker; 1 = not at all helpful to 4 = extremely helpful), their 
overall satisfaction with the program (1 = very dissatisfied to 4 = very satisfied) and whether 
they would recommend the program to other breast cancer survivors (1 = definitely not to 4 
= definitely would) [54].
Statistical analyses
The primary outcome of proportion of participants who completed the 3-month and 6-month 
assessments was calculated along with an exact 95% confidence interval. Given the small 
sample size and that data were considerably skewed, we conducted nonparametric tests. 
Baseline demographic characteristics were compared among groups using Kruskal-Wallis 
tests for continuous variables or Fisher’s exact tests of independence for categorical 
variables. Descriptive statistics (percentages, medians, interquartile ranges) of study 
measures (demographics, anthropometrics, clinical measurements, and behaviors) are 
reported at baseline, 3 months and 6 months. Change in anthropometric, clinical and 
behavioral outcomes, and adherence to daily self-weighing from baseline to 6 months 
among the three groups were compared using Kruskal-Wallis tests. Changes scores and 
analyses are reported on participants with complete data at baseline and 6 months (n=33 out 
of 35 for weight), given the pilot nature of the study and the consistency of findings with 
intention-to-treat analyses (i.e., when missing data were imputed with the last observation 
carried forward). Within each group, change scores were tested to examine if they were 
significantly different from 0 using Wilcoxon signed rank tests. Pairwise contrasts between 
each intervention group and the control group were evaluated with Wilcoxon rank sum tests 
without correcting for multiple comparisons as the study purpose was to examine feasibility. 
Spearman rank correlations were conducted to assess the association between total days of 
self-monitoring and weight change. To evaluate adherence to weight management strategies, 
self-weighing perceptions, program acceptability and satisfaction with the interventions, we 
used Mann-Whitney U tests to compare responses between the two intervention groups 
(n=23). All analyses were conducted using SPSS 22.0 (Chicago, IL).
RESULTS
Enrollment and Baseline Characteristics
We enrolled 35 women over a nine month period of recruitment, averaging about 4 
participants per month (Figure 1). Of 487 potential contacts, 162 were screened (33.3% 
response rate), 50 were eligible (30.9% of 162), and 35 completed baseline assessments and 
were randomized to the three groups (21.6% of 162, 7.2% enrollment rate). Table 2 shows 
baseline characteristics by study groups. Participants were on average (SD) 53.0 (9.1) years 
of age, obese (BMI of 33.9 (5.9) kg/m2), with baseline weight of 88.4 (16.7) kg, and 3.1 
(2.3) years post-diagnosis. Over half were employed full-time (63%) with college degrees 
(66%), and most had stage I–II breast cancer (77%), hypertension (57%) and were post-
menopausal (80%). At baseline, the majority of women reported weighing themselves less 
than once a week (77.1%) over the past 3 months, with only 8.6% reporting daily weighing. 
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Most women reported never or hardly ever self-monitoring their diet (80.0%) or physical 
activity (82.9%) over the previous 3 months. There were no significant differences in 
baseline characteristics across the three groups.
Retention and Adherence
Table 3 shows retention rates and data regarding adherence to self-monitoring and program 
utilization by group. At 3 months, a total of 94.3% of participants completed both in-person 
and online assessments. Participant retention rates at 6 months were 97.1% for the in-person 
visit and 94.3% for online measurements. Retention rates at 3 months did not differ among 
groups for clinic visits or online assessments, and neither did completion of 6-month clinic 
visits or online questionnaires. No adverse events were reported during the course of the 
study.
Self-monitoring—Among the INT+ and INT groups, the median total days weighed was 
154 (91.7%) and 106 (63.1%) out of 168 prescribed days compared with 11 total days 
(6.5%) in the control group (p<0.0005 between groups). Over 80% of INT+ participants 
weighed 5 or more days per week on average, and this proportion significantly differed 
between groups. Within the INT+ group, 72.7% of participants wore activity trackers 5 or 
more days per week, and median total days worn was 162 out of 168 days (96.4% of 
prescribed days). Both intervention groups maintained self-weighing days per week over the 
course of the study with no group differences and no decrease over time from week 1 to 24 
(INT+, p = 0.414; INT, p = 0.140). Similarly, activity tracking remained consistent over time 
in the INT+ group.
Program utilization—There were no differences between intervention groups in the use 
of emailed intervention components. Ninety percent of INT+ and 100% of INT participants 
reported reading some-all/most of the email lessons, while 90.9% and 100% read some-all/
most of the email feedback. INT+ participants reported significantly more frequent tracking 
intake using an app or website (p=0.037) and wearing a pedometer or activity monitor (p = 
0.001) compared to INT participants. Both groups reported comparable use of other weight 
management strategies, including making 100-calorie diet changes to reduce intake, 
increasing daily steps, and exercising at least 5 days per week.
Effects
Weight change and clinical measures—Table 4 shows study outcomes by each group 
over time. Median weight change from baseline to 3 months was significant among 
intervention groups, but not the control group (INT+, p=0.008 compared to baseline; INT, p 
= 0.023; CON, p = 0.678) (Figure 2). At 6 months, median weight change was −0.94% in 
the INT+ (p = 0.075 compared to baseline) and −0.22% in the INT group (p = 0.463) versus 
a 0.18% gain (p = 0.327) in the control group. In comparison with the control group, there 
was greater weight change over 6 months in the INT+ group (p = 0.067), but not the INT 
group (p = 0.357). The proportion of INT+, INT and CON participants that were at or below 
baseline weight was 72.7%, 53.8% and 44.4% respectively (X2 (2), N = 33) = 1.756; p = 
0.454, Cohen’s d = .64, d = .18 vs. CON). Total days of self-weighing was significantly 
correlated with weight change at both 3 and 6 months (3 months: r = −.490, p = 0.004; 6 
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months, r = −.629, p < 0.0005), while total PA days were not (3 months: r = −.169, p = 
0.619; 6 months, r = −.160, p = 0.639).
INT+ group participants decreased BMI over 6 months, which was significantly different 
from the control group (p = 0.046 between groups). At 6 months, the INT+ group had 
significantly decreased waist circumference (p=0.021 compared to baseline) and systolic 
blood pressure (p=0.047 compared to baseline). No significant differences were observed in 
other clinical measurements.
Diet and physical activity behaviors—There were no differences between groups over 
time in changes in dietary intake and energy expenditure from physical activity (Table 4). 
However, from baseline to 6 months, the INT+ group reported a significant 432 kcal 
increase in energy expenditure per week (p = 0.028 compared to baseline), and there was a 
trend toward decreased dietary intake per day in this group (p = 0.062 compared to 
baseline).
Perceptions of Daily Self-weighing
Both intervention groups had favorable perceptions of weighing themselves daily at 6 
months with no differences between groups. Interventions participants reported that daily 
self-weighing was easy to do [Mdn(IQR): INT+, 8 (4−8) vs. INT, 6 (2−7), p = 0.206], easy 
to remember (INT+, 7 (7−8) vs. INT, 5 (2.3−7.8), p = 0.058), helpful (INT+, 7.5 (5−8) vs. 
INT, 7.5 (5.3−8), p = 0.951), and positive (INT+, 7 (4−8) vs. INT, 8 (3.5−8), p = 0.680). 
Both groups endorsed being very likely to continue daily weighing after the program (INT+, 
8 (5−8) vs. INT, 8 (3.5−8), p = 0.579). With respect to negative perceptions, intervention 
groups had comparably low ratings for whether they perceived daily self-weighing to be 
anxiety provoking (INT+, 2 (1−5) vs. INT, 2 (1−4.5), p = 0.942), frustrating (INT+, 2 (1−4) 
vs. INT, 2 (1−5), p = 0.944), or made them feel self-conscious (INT+, 2 (1−6) vs. INT, 3 
(1−4), p = 0.925).
Satisfaction and Acceptability of Approaches
Participant ratings of program approaches are shown in Table 3. Consistent with 
participants’ positive perceptions about self-weighing, the program feature that women 
across both groups found most helpful for reaching their weight goals was the smart scale. 
INT+ participants also rated the activity tracker as extremely helpful. Other most highly 
rated program components were the email feedback and working to change the way they 
thought about making healthy changes. Participants in both intervention groups highly 
ranked the helpfulness of information received in the program for controlling their weight 
and the approach of making 100-calorie dietary changes. Although both intervention groups 
reported that it was somewhat difficult to make the recommended changes in eating and, 
participants in both groups felt highly confident that they would continue to follow the 
approaches taught in the program. Furthermore, women reported that the approach they were 
taught would help them prevent weight gain. Most INT+ (100%) and INT (91.7%) 
participants were somewhat satisfied or very satisfied with the program (p = 1.00 between 
groups), and 100% of both groups reported they would recommend the program to other 
breast cancer survivors.
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DISCUSSION
This study demonstrates the feasibility of recruiting and retaining African American breast 
cancer survivors to safely participate in a weight gain prevention intervention using a self-
regulation framework with objective monitoring and tailored feedback on weight only or 
weight plus activity. Our innovative technology-delivered approach, which capitalized on the 
use of newer technology without requiring regular face-to-face contact, focused on daily 
self-weighing and small behavior changes, included emailed behavioral skills training and 
tailored feedback, and achieved high rates of retention and adherence after 6 months. Among 
the INT+ group that self-monitored both weight and activity, the improvements in weight, 
energy expenditure, and dietary intake over time were encouraging and show initial promise 
for a self-regulation approach to preventing weight gain in this population of cancer 
survivors compared to controls. Further, participants in both intervention groups were 
satisfied with the program, had favorable perceptions of both daily self-weighing and small 
behavior changes, and were likely to continue using these key approaches taught in the self-
regulation intervention. To our knowledge, this is one of the few randomized trials of 
lifestyle interventions focused on weight gain prevention in African American breast cancer 
survivors and the first to report their experiences using a technology-delivered intervention 
with objective measures of self-weighing and activity tracking. As such, our findings are 
encouraging for future studies and the development of accessible and scalable interventions 
for underserved cancer survivors in need of lifestyle interventions.
A third of breast cancer survivors contacted were screened for the study, with 70% of 
eligible participants (7.2% of potential contacts approached) enrolling in the trial. Although 
our recruitment rate was low, it was comparable to the 5.7% recruitment rate in pooled 
analyses of distance-based diet and exercise intervention trials among predominantly White 
cancer survivors that also used recruitment mailings [55]. Among our recruitment strategies 
used, mass mailings yielded the largest number of enrolled participants (16 out of 35, 48%). 
The WELL Body study achieved high retention rates of 94% at 3 months and 97% at 6 
months. Previous distance-based lifestyle intervention studies among cancer survivors have 
reported similar rates of study completion over 90% [32,55]. It is noteworthy that our 
retention rates were higher than the 71.0−90.5% range among randomized controlled trials 
in a systematic review of weight loss interventions for women with breast cancer [38], 
almost all of which were delivered face-to-face, and higher than the 71.0−91.7% completion 
rates in previous trials among African American breast cancer survivors [14–18]. That 
attrition rates in this study were lower than other web-based lifestyle interventions among 
cancer survivors is also encouraging [32]. The women who enrolled may have had higher 
motivation to adopt behavior changes and thus to remain in the study [55]. High retention 
rates also may have been a function of the technology-delivered intervention approach, 
which obviated the need for participants to travel for face-to-face sessions or spend time on 
telephone counseling, adherence and satisfaction with different intervention components, or 
rapport built with the interventionist. Together, these findings demonstrate the feasibility of 
recruiting and retaining African American breast cancer survivors to participate in a 
distance-based lifestyle intervention program and suggest that a technology-delivered 
intervention may lead to improved retention and engagement.
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Previous studies have shown that regular self-weighing is associated with better weight gain 
prevention [26]. Similarly, we found that more frequent self-weighing was strongly 
correlated to weight loss at 6 months. Mean (SD) weight loss after 6 months in both 
intervention groups combined was −1.9 (4.3) kg on average or −2.2 (5.0)% (range: 20% loss 
to 3.4% gain) of initial body weight, and 63% of intervention participants were at or below 
their baseline weight. Although the focus of our intervention was on weight gain prevention, 
these weight losses are similar to those found in previous weight loss interventions among 
African American breast cancer survivors which have ranged from 0.8 to 3.3% and were all 
delivered in face-to-face individual or group sessions, some including telephone counseling 
[14–18,56]. Similar to these interventions, we found improvements in the INT+ group over 
time in BMI [14–16,56], waist circumference [15,56], systolic blood pressure [15], energy 
expenditure [14,16] and a trend toward reduced caloric intake [14,16]. The lack of changes 
in lipids and metabolic measures is consistent with other six-month behavioral weight loss 
interventions in breast cancer survivors [56,57].
This is the first study to encourage daily-self weighing as a self-regulation approach for 
weight gain prevention among breast cancer survivors. Of the few other weight gain 
prevention trials that have encouraged daily weighing within lifestyle interventions 
[26,30,31] most have relied on self-reported measures of weighing behaviors. An 
intervention among first-year college students that included an introductory video lecture, 
encouraged daily self-weighing, provided Wi-Fi enabled scales without access to an app or 
online profile, and emailed daily feedback with a graph of weight data produced mean (SD) 
weight losses of −0.19 (2.89) kg at 6 months and −0.47 (3.66) kg at 1 year, one-tenth of the 
weight loss achieved in this study at 6 months [31]. The median frequency of self-weighing 
in the first 6 months was 5.0 days per week compared to 6.4 (INT+) and 4.4 (INT) days per 
week in our study. Although our intervention had similar components, WELL Body 
participants were able to view weight (and activity) graphs and trends via their individual 
profile on the commercial website and app, received weekly lessons on behavioral skills, 
instructions to make small diet changes and gradually increase activity, and weekly emailed 
feedback encouraging adherence to daily weighing (and activity tracking). Given the 
multiple intervention strategies used and different study populations, we are unable to isolate 
the specific effects of daily self-monitoring and other components delivered on weight 
outcomes. However, adherence to and acceptability of daily weighing were high among 
intervention participants, especially those in the INT+ group, in the context of a technology-
delivered weight gain prevention. Further evaluation of this self-regulation intervention 
approach among breast cancer survivors is necessary.
While both intervention groups demonstrated small, but significant within group weight 
losses at 3 months, only the INT+ group (i.e., used wireless scale and activity tracker) 
showed a trend toward maintaining weight losses at 6 months relative to weight gain in the 
control group. In general, the magnitude of changes in eating and exercise behaviors 
appeared to be greater in this group compared with the INT group that only received the 
scale. Both intervention groups reported comparable use of email lessons, feedback and 
weight management strategies, found the smart scale and tailored feedback to be helpful for 
reaching their weight goals, and indicated highly positive perceptions about daily self-
weighing and satisfaction with the program approach. Thus, the improvements in the INT+ 
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group may be explained in part by the significantly higher levels of adherence to self-
monitoring and use of the activity tracker. Over 81% of INT+ group participants, more than 
twice the amount of INT group participants, weighed themselves 5 days or more on average 
over the course of the study, and 73% wore trackers on 5 or more days. Furthermore, INT+ 
participants found the activity tracker to be extremely helpful and reported more frequent 
use of an app or website to track dietary intake and use of an activity monitor. While the 
activity tracker may have contributed to improved engagement, better adherence and 
subsequent changes in diet and activity, it is unclear whether the improvements among INT+ 
participants were attributable to the tracker alone, to receiving tailored feedback about 
adherence and behaviors based on tracker data, or some synergistic effects of these 
components with use of the scale. Recent studies have shown that people stop using trackers 
after only a few weeks of wear [58,59], and a systematic review on the effectiveness of 
accelerometer use on weight outcomes found that these devices have small effects, and the 
body of research is relatively small and limited by poorly designed comparison groups [60]. 
Thus, future studies to isolate the effects of activity trackers and feedback on weight control 
and to sustain longer-term engagement and adherence are warranted. Altogether, our 
findings suggest that implementation of a self-regulation approach that employs both a 
wireless scale and activity tracker may be useful for promoting weight gain prevention in 
breast cancer survivors.
This is one of the few lifestyle intervention studies specifically for African American breast 
cancer survivors and the first study to evaluate a distance-based technology-delivered 
approach. Although the small sample size limited our statistical power to detect significant 
group differences and conduct multivariate analyses, the achievement of modest weight 
losses within the INT+ group using a less intensive intervention approach is notable. Our 
study sample included only women that had regular access to the Internet and thus may not 
be generalizable to breast cancer survivors with more limited technology resources. The lack 
of blinded outcome assessors was a study limitation; as the interventionist was also 
responsible for data collection, this may have influenced participants’ adherence and 
completion of follow-up assessments. Other sources of potential bias included incomplete 
outcome data from a few participants and self-report measures that may have resulted in 
over- or underestimates of dietary intake, energy expenditure and other outcomes. As both 
intervention groups received a multicomponent intervention, another study limitation is our 
inability to determine the independent effects of components on weight outcomes. Thus, it is 
unknown whether daily self-weighing, the tracker, email lessons or tailored feedback based 
on objective weight, with or without activity, or some combination of these impacted weight. 
Future studies using alternate study designs (e.g., fractional factorial) could be conducted to 
identify the most efficacious components for intervention optimization and further 
evaluation.
In summary, this study indicates that a distance- and technology-based intervention focused 
on daily self-weighing and small behavior changes was feasible and acceptable among 
African American breast cancer survivors. Given that breast cancer survivors are at risk for 
weight gain and associated comorbid conditions, and few weight loss interventions have 
resulted in clinically meaningful weight loss outcomes among African American breast 
cancer survivors, there is a need for more effective weight management interventions for this 
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population. Our intervention, which focused on weight gain prevention using technology-
enabled daily self-monitoring of weight and activity, demonstrated weight change 
comparable to previous weight loss interventions in African American breast cancer 
survivors. Weight gain prevention may be a useful and potentially sustainable approach to 
reducing disease risks and mortality related to weight gain and obesity after breast cancer. 
Future evaluation of this self-regulation intervention approach in a larger trial over a longer 
period of time is warranted to determine the most effective strategies for preventing weight 
gain among breast cancer survivors.
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Figure 1. CONSORT diagram of study enrollment and retention in WELL Body 6-month 
randomized controlled trial
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Figure 2. Median percent weight change (IQR) during WELL Body trial by group
*p = 0.023 within group compared to baseline. **p = 0.008 within group compared to 
baseline.
#p = 0.075 within group compared to baseline. +p = 0.067 vs. control group.
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Table 1
Overview of WELL Body self-regulation intervention
Key Intervention Concept Intervention Approach Components Used
Self-monitoring weight Self monitor weight daily using
wireless scale. Use weight as
indicator of whether diet and
activity changes are working.
Smart scale to monitor weight
Email lessons
Tailored feedback email
Dietary changes recommended
for maintaining weight (green
zone)
Make one small change in diet
every day (roughly equivalent to
100 calories).
Email lessons
Physical activity changes
recommended for maintaining
weight (green zone)
Gradually increase moderate-
intensity exercise to 150–225
min/week (30–45 min/day on 5
days/week) over 6 months.
(INT+ only: Monitor activity
daily using activity tracker).
Email lessons
Tracker to monitor activity
Tailored feedback email
Actions to take in yellow zone
(weight is 3–4 pounds above
baseline weight)
Make additional small changes in
eating (e.g., make at least 1 small
change at every meal), weigh
daily and meet weekly exercise
goal. Use problem-solving skills,
with focus on changing
surrounding environment to
support small changes.
Smart scale to monitor weight
Email lessons
Tailored feedback email
Actions to take in red zone
(weight is ≥5 pounds above
baseline weight)
Make additional small changes in
eating (e.g., make at least 1 small
change at every meal and snack),
weigh daily and meet weekly
exercise goal.
Smart scale to monitor weight
Email lessons
Tailored feedback email
INT+ Self-regulation intervention plus activity monitoring
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Table 2
Baseline characteristics of participants in the WELL Body trial
Variable Control
(n=11)
Intervention
(n=13)
Intervention+
(n=11)
P value
Age, y
  M(SD) 54.4 (11.1) 52.6 (9.4) 52.2 (6.9) .843
  Range 35–71 36–67 45–65
Education level, n (%) .246
  HS degree/less 3 (27.3) 2 (15.4) 0 (0.0)
  Some college 3 (27.3) 3 (23.1) 1 (9.1)
  College degree+ 5 (45.5) 8 (61.5) 10 (90.9)
Marital Status, n (%) 1.000
  Married 5 (45.5) 7 (53.8) 5 (45.5)
  Other 6 (54.5) 6 (46.2) 6 (54.5)
Employed Full-time, n (%) 6 (54.5) 7 (53.8) 9 (81.1) .351
Income, n (% <$60,000/year) 6 (54.5) 5 (50.0) 5 (50.0) 1.000
Current/former smoker, n (%) 2 (18.2) 3 (23.1) 1 (9.1) .855
Mean Weight (SD), kg 93.8 (20.8) 85.5 (15.3) 86.3 (13.9) .438
Mean BMI (SD), kg/m2 35.3 (6.5) 32.7 (6.1) 34.0 (5.3) .570
Months since diagnosis, Med (IQR) 50 (38) 50 (50) 30 (9) .074
Cancer stage, n (%) .154
  Stage I 5 (45.5) 1 (7.7) 5 (45.5)
  Stage II 5 (36.4) 7 (53.8) 5 (45.5)
  Stage III 2 (18.2) 5 (38.5) 1 (9.1)
Anti-hormone therapy, n (% current) 0 (0) 3 (23.1) 1 (9.1) .355
Breast Cancer surgery, n (%) 11 (100) 12 (92.3) 11 (100) 1.00
Chemotherapy, n (%) 9 (81.8) 10 (76.9) 9 (81.8) .855
Radiation, n (%) 8 (72.7) 11 (84.6) 9 (81.8) .871
Co-morbid conditions, n(%)
  Hypertension 6 (54.5) 7 (53.8) 7 (63.6) .915
  High cholesterol 3 (27.3) 3 (23.1) 0 (0.0) .268
  Type 2 diabetes 3 (27.3) 2 (15.4) 2 (18.2) .871
Medications, n (%)
  Hypertension 6 (54.5) 8 (61.5) 7 (63.6) 1.000
  High cholesterol 3 (27.3) 2 (15.4) 0 (0) .239
  Diabetes 2 (18.2) 2 (15.4) 2 (18.2) 1.000
Menopausal status, n (%) 1.000
  Premenopausal 2(18.2) 3 (23.1) 2 (18.2)
  Postmenopausal 9 (81.8) 10 (76.9) 9 (81.8)
Energy intake, kcal/d (SD) 1698 (561) 1695 (669) 1864 (460) .731
% Calories from Fat 40.4 (8.5) 37.6 (9.3) 41.9 (6.3) .433
Mean energy expenditure (SD), kcal/day 441 (462) 616 (522) 701 (948) .653
Self-monitoring frequency, n (%)
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Variable Control
(n=11)
Intervention
(n=13)
Intervention+
(n=11)
P value
  Weighing, Less than 1×/week 8 (72.7) 12 (63.6) 7 (63.6) .467
  Diet, Never/ hardly ever 8 (72.7) 10 (76.9) 10 (90.0) .661
  PA, Never/ hardly ever 9 (81.8) 11 (84.6) 9 (81.8) 1.000
SD standard deviation, IQR interquartile range
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Table 3
Adherence to assessments, self-monitoring, program utilization, and acceptability of approaches by 
participants in the WELL Body trial
Variable Control
(n=11)
Intervention
(n=13)
Intervention+
(n=11)
P value
Clinic visit completion, % (95% CI)
  3 months 90.9 (58.7, 99.8) 92.3 (64.0, 99.8) 100 (71.5, 100) 1.000
  6 months 90.9 (58.7, 99.8) 100 (75.3, 100) 100 (71.5, 100) 1.000
Online survey completion, % (95% CI)
  3 months 90.9 (58.7, 99.8) 92.3 (64.0, 99.8) 100 (71.5, 100) 1.000
  6 months 90.9 (58.7, 99.8) 92.3 (64.0, 99.8) 100 (71.5, 100) .629
Self-monitoring
Self-weighing frequency over 6 months
  Days per week, Mdn (IQR) 0.5 (0, 1.8) 4.4 (3.2, 5.9) 6.4 (5.4, 6.7) <.0005
  ≥5 days per week, n(%) 0 (0) 5 (38.5) 9 (81.9) <.0005
Activity tracking frequency over 6 months
  Days per week, Mdn (IQR) - - 6.8 (3.5) -
  ≥5 days per week, n(%) - - 8 (72.7) -
Self-weighing frequency by week
  Week 1, Mdn (IQR) 1 (0, 2) 6 (4, 7) 7 (4, 7) <.0005a
  Week 13, Mdn (IQR) 0 (0, 1) 5 (2.5, 7) 7 (5, 7) <.0005a
  Week 24, Mdn (IQR) 0 (0, 0) 4 (0, 7) 7 (5, 7) <.001a
Activity tracking frequency by week
  Week 1, Mdn (IQR) - - 7 (5, 7)
  Week 13, Mdn (IQR) - - 7 (7, 7)
.715b
  Week 24, Mdn (IQR) - - 5 (0, 7)
.172b
Program utilization
  Read some-all/most email lessons, n (%)c - 12 (100) 9 (90) .455
  Read some-all/most email feedback, n (%)d - 12 (100) 10 (90.9) .478
Weight management strategies, M(SD)d,e
  Reduced dietary intake w/100-calorie changes - 4.8 (2.0) 5 (1.8) .797
  Tracked intake using app/website - 1.9 (1.6) 4.3 (3.1) .037
  Increased daily steps - 5.3 (1.8) 6.0 (2.1) .348
  Active at least 5 days per week - 4.8 (1.8) 6 (2.0) .124
  Wore a monitor to track activity - 3.3 (2.5) 7.0 (1.5) .001
Acceptability of approaches, Mdn (IQR)d
  Smart scalef - 2.5 (2, 4) 4 (3, 4) .197
  Activity trackerf - - 4 (3, 4)
  Email feedbackf - 3 (2, 3) 3 (2.8, 4) .521
  Changing thoughts about making healthy changesf - 3 (2, 4) 3 (2.5, 4) .420
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Variable Control
(n=11)
Intervention
(n=13)
Intervention+
(n=11)
P value
  Information on weight controlg - 8 (6.3, 8) 8 (5, 8) 1.000
  Focus on making100-calorie diet changesg - 7.5 (4.8, 8) 7 (5, 8) .584
  Difficult making recommended diet changesh - 4 (2, 5.75) 6 (4, 6) .082
  Difficult making recommended activity changesh - 5 (2.25, 6) 4 (3, 6) .995
  Confidence in continuing eating approachi - 8 (5.3, 8) 7 (5, 8) .447
  Confidence in continuing exercise approachi - 7.5 (5.3, 8) 7 (5, 8) .792
  Confident that approach helps prevents weight gaini - 8 (5, 8) 7 (6, 8) .716
ap=value comparing Intervention vs. Intervention+: p=.248 at 1 week, p=.272 at 13 weeks, p=.175 at 24 weeks.
bp-value comparing to week 1.
c
Results based on participants with response at 24 weeks (i.e., n=12 for Intervention, n=10 for Intervention+).
d
Results based on participants with response at 24 weeks (i.e., n=12 Intervention, n= 11 Intervention+).
e1 = not at all to 8 = always
f1 = not at all helpful to 4 = extremely helpful
g1 = not at all helpful to 8 = extremely helpful
h1 = very easy to 8 = very difficult
i1 = not confident to 8 = very confident
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